Ozekibart
- Generic Name
- Ozekibart
- Drug Type
- Biotech
- CAS Number
- 2539847-03-3
- Unique Ingredient Identifier
- R0GA5221D4
- Background
Ozekibart is a tetravalent recombinant humanized IgG1 agonist antibody targeting the human TRAIL death receptor 5 (DR5). It is being investigated for the treatment of chondrosarcoma.
Study of INBRX-109 in Conventional Chondrosarcoma
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Inhibrx Biosciences, Inc
- Target Recruit Count
- 201
- Registration Number
- NCT04950075
- Locations
- 🇺🇸
Precision NextGen Oncology & Research Center, Beverly Hills, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸University of Oklahoma - Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- Conditions
- Colorectal AdenocarcinomaEwing Sarcoma
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Inhibrx Biosciences, Inc
- Target Recruit Count
- 321
- Registration Number
- NCT03715933
- Locations
- 🇺🇸
Precision NextGen Oncology and Research, Beverly Hills, California, United States
🇺🇸University of California, San Francisco (UCSF), San Francisco, California, United States
🇺🇸Children's Hospital of Philadelphia- Center for Childhood Cancer Research, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.